Genentech Archives

News and Trends 21 Sep 2016

German Biotech allies with Genentech in battle for Cancer Vaccine

BioNTech has turned up the heat in the race to bring an mRNA immunotherapy for cancer to the clinic. The German biotech has partnered with American giant Genentech in a massive deal with almost €300M upfront. Europe’s largest private biotech, BioNTech, has partnered up with Genentech to produce individualized mRNA-based cancer therapies. The collaboration aims […]

September 21, 2016 - 3 minutesmins - By Evelyn Warner

Best in Biotech 2 Aug 2016

7 Books to turn you into a Biotech Genius over the Summer

As summer is approaching its peak, we thought that you would like to discover some of the Biotech books we love the most. This list (without any particular order) will give you a broad choice of topics, from entrepreneurial journeys to scientific breakthroughs. Enjoy reading and be inspired by these amazing stories! The Antidote: Inside the […]

August 2, 2016 - 4 minutesmins - By Joachim Eeckhout

Genentech birthday 40 biotechnology cohen boyer swanson

News and Trends 11 Apr 2016

Modern Biotechnology is Now 40 – Happy Birthday!

Genentech has turned 40 years old this month – quite a milestone for the pioneer of modern biotechnology, which is still rocking it in San Francisco, US. It all began with an experiment conducted by a team led by Herbert Boyer of the University of California San Francisco (UCSF), studying antibiotic resistance plasmids in E. […]

April 11, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 9 Feb 2016

When the Biggest Tech Investors Go Wild for Biotech

Biotech is catching new investors’ interest. Just in 2015, Google Ventures, the accelerator Y Combinator, Andreessen Horowitz (one of the most successful early-stage investment funds in the Valley) and Peter Thiel (founder of Paypal) showed their interest in Biotech. Why? And why now? Andreessen Horowitz is the investment fund created by Marc Andreessen (founder of Netscape) and […]

February 9, 2016 - 5 minutesmins - By Philip Hemme

cohen boyer patents standford gene editing technology biotech

News and Trends 3 Dec 2015

History of Biotech: How the “First” Biotech Patent Generated Millions

The Cohen-Boyer patents were now issued 35 years ago at Stanford University… so what were they and how did they shape the Modern Biotechnology Field? Recombinant DNA (rDNA) products provided a new technology platform for a range of industries, resulting in over US$35 billion in sales for an estimated 2,442 new products. After Genentech was […]

December 3, 2015 - 5 minutesmins - By Marie Godar

News and Trends 23 Oct 2015

#Sorry: The World-leading Oncology Company fails in Phase III

Antibody Drug Conjugate is a smart way to improve chemotherapy. That is the strategy of Roche / Immunogen‘s drug Kadcyla®, which has just failed in Phase III clinical trial to extend its indications. Here are the facts… Antibody Drug Conjugate is at the boundary between chemical and biological drug. The principle is pretty simple; once the antibody fixes to […]

October 23, 2015 - 2 minutesmins - By Jerome Topsent

News and Trends 9 Oct 2015

TauRX, the leading Alzheimer-focused Biotech, earns funding after Phase II breakthrough

The Tau protein has already been implicated in the onset of Alzheimer’s, with many biotechs on the hunt for a preventative therapy. Now, a University of Aberdeen (UK) associated biotech, TauRX, have drawn €120M for their phase III therapy. TauRX is a spin-off biotech from the University of Aberdeen in Scotland (UK) where its clinical […]

October 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 8 Oct 2015

Rabbit Antibodies proven to be more specific than Mice in Immuno-oncology PD-L1 Research

Abcam is a Cambridge (UK) Biotech who have developed a monoclonal antibody (mAB) production platform from rabbits. This platform is developed for a much more specific immunohistochemical alternative to the traditional Rodent equivalents. Now the most recent generation of mAbs from this platoform is able to detect PD-L1 tumor proteins for immuno-oncology research. The conventional […]

October 8, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 29 Sep 2015

Will Roche lose its Worldwide Leading position in Cancer treatments?

Roche is the worldwide leader in cancer treatments, but it’s threatened by the increasing competition of biosimilars and the development of next-generation cancer drugs. Is there a risk for the “biggest Biotechnology company worldwide” to lose its leading position on the lucrative anti-cancer business? The Swiss giant makes massive amount of cash with its cancer treatments, […]

September 29, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 1 Sep 2015

Genentech’s Sean Bohen defects to AstraZeneca as CMO

AstraZeneca‘s Senior management team gets reinforced by Sean Bohen, a top executive from Roche‘s subsidiary Genentech. Starting in two weeks, he will push late-stage treatments to the market. It’s been two months since two senior manager left the struggling AstraZeneca. Among them, Briggs Morrison, who left to become new CEO of Syndax. To replace him, […]

September 1, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 19 Aug 2015

Top 5 Biotech Books to Enjoy your Summer on the Beach

Summer is a great time to read books and get inspired for the year to come. Here’s a Top 5 list of my recommendations to read before summer ends. 1. Genentech: The Beginnings of Biotech Genentech is considered the founder of the Biotech industry in the late 80s. It started from breakthrough science, crazy scientists and very risk-taking […]

August 19, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 12 Aug 2015

Roche and Clovis combine drugs to fight lung cancer, the most common cancer worldwide

Roche‘s subsidiary Genentech joined forces with NASDAQ-listed Clovis Oncology to evaluate a novel combination therapy for the treatment of advanced EGFR-mutant non-small cell lung cancer (NSCLC). Its anti PD-L1 cancer immunotherapy and Clovis’ rociletinib will enter Phase Ib/II in 2015. With 1.35 million new cases annually, lung cancer is the most common cancer worldwide. In […]

August 12, 2015 - 2 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us